The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an ...

The FDA granted accelerated approval to mosunetuzumab (Lunsumio; Genentech), a CD20/CD3 bispecific T-cell engager administered as a subcutaneous injection for patients with relapsed or refractory ...

BISHKEK, Dec 1 (Reuters) - OSCE election observers said on Monday that a weekend parliamentary election in Kyrgyzstan had been efficiently run, but stifled by a restrictive campaign environment and ...

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...